168 related articles for article (PubMed ID: 18491117)
1. [Cytokine blockade - a promising therapeutic option in SLE].
Aringer M; Feierl E; Smolen J
Z Rheumatol; 2008 Jul; 67(4):315-7. PubMed ID: 18491117
[TBL] [Abstract][Full Text] [Related]
2. Cytokine disturbances in systemic lupus erythematosus.
Jacob N; Stohl W
Arthritis Res Ther; 2011 Jul; 13(4):228. PubMed ID: 21745419
[TBL] [Abstract][Full Text] [Related]
3. Induction of severe systemic lupus erythematosus by TNF blockade and response to anti-IL-6 strategy.
Adler S; Kolev M; Varisco PA; Tham M; von Gunten M; Tappeiner C; Villiger PM
J Allergy Clin Immunol; 2013 Apr; 131(4):1235-7, 1237.e1. PubMed ID: 23154083
[No Abstract] [Full Text] [Related]
4. Effects of anti-CD4 antibodies on the release of IL-6 and TNF-alpha in whole blood samples from patients with systemic lupus erythematosus.
Brink I; Thiele B; Burmester GR; Trebeljahr G; Emmrich F; Hiepe F
Lupus; 1999; 8(9):723-30. PubMed ID: 10602444
[TBL] [Abstract][Full Text] [Related]
5. Induction of severe systemic lupus erythematosus by TNF blockade and response to an anti-IL-6 strategy: role of IL-17?
Shin JI
J Allergy Clin Immunol; 2013 Nov; 132(5):1257. PubMed ID: 24176686
[No Abstract] [Full Text] [Related]
6. Cytokine inhibition as a strategy for treating systemic lupus erythematosus.
Clark DN; Markham JL; Sloan CS; Poole BD
Clin Immunol; 2013 Sep; 148(3):335-43. PubMed ID: 23200699
[TBL] [Abstract][Full Text] [Related]
7. Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention.
Aringer M; Smolen JS
Lupus; 2004; 13(5):344-7. PubMed ID: 15230290
[TBL] [Abstract][Full Text] [Related]
8. Lessons for lupus from tumour necrosis factor blockade.
De Bandt M
Lupus; 2006; 15(11):762-7. PubMed ID: 17153848
[TBL] [Abstract][Full Text] [Related]
9. The role of tumor necrosis factor-alpha in systemic lupus erythematosus.
Aringer M; Smolen JS
Arthritis Res Ther; 2008; 10(1):202. PubMed ID: 18226185
[TBL] [Abstract][Full Text] [Related]
10. MIF promotes a differential Th1/Th2/Th17 inflammatory response in human primary cell cultures: Predominance of Th17 cytokine profile in PBMC from healthy subjects and increase of IL-6 and TNF-α in PBMC from active SLE patients.
De la Cruz-Mosso U; García-Iglesias T; Bucala R; Estrada-García I; González-López L; Cerpa-Cruz S; Parra-Rojas I; Gámez-Nava JI; Pérez-Guerrero EE; Muñoz-Valle JF
Cell Immunol; 2018 Feb; 324():42-49. PubMed ID: 29397904
[TBL] [Abstract][Full Text] [Related]
11. B-cell-targeted therapy for systemic lupus erythematosus.
Sabahi R; Anolik JH
Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
Aringer M; Graninger WB; Steiner G; Smolen JS
Arthritis Rheum; 2004 Oct; 50(10):3161-9. PubMed ID: 15476222
[TBL] [Abstract][Full Text] [Related]
13. Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-α, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients.
Fleischer V; Sieber J; Fleischer SJ; Shock A; Heine G; Daridon C; Dörner T
Arthritis Res Ther; 2015 Jul; 17(1):185. PubMed ID: 26183319
[TBL] [Abstract][Full Text] [Related]
14. [Proinflammatory cytokines in inactive lupus erythematosus patients].
Lesiak A; Sysa-Jedrzejowska A; Narbutt J; Lukamowicz J; Robak E; Wozniacka A
Przegl Lek; 2005; 62(9):838-42. PubMed ID: 16541713
[TBL] [Abstract][Full Text] [Related]
15. From mechanism to therapies in systemic lupus erythematosus.
Paley MA; Strand V; Kim AH
Curr Opin Rheumatol; 2017 Mar; 29(2):178-186. PubMed ID: 28118202
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic blockade of TNF in patients with SLE-promising or crazy?
Aringer M; Smolen JS
Autoimmun Rev; 2012 Mar; 11(5):321-5. PubMed ID: 21619949
[TBL] [Abstract][Full Text] [Related]
17. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus.
Yao Y; Richman L; Higgs BW; Morehouse CA; de los Reyes M; Brohawn P; Zhang J; White B; Coyle AJ; Kiener PA; Jallal B
Arthritis Rheum; 2009 Jun; 60(6):1785-96. PubMed ID: 19479852
[TBL] [Abstract][Full Text] [Related]
18. Th1/Th2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor alpha protective?
Gómez D; Correa PA; Gómez LM; Cadena J; Molina JF; Anaya JM
Semin Arthritis Rheum; 2004 Jun; 33(6):404-13. PubMed ID: 15190525
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal Antibody Drugs for Systemic Lupus Erythematosus.
Kamenarska ZG; Hristova MH; Vinkov AI; Dourmishev LA
Folia Med (Plovdiv); 2015; 57(2):89-92. PubMed ID: 26933777
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of infliximab in active SLE: a pilot study.
Uppal SS; Hayat SJ; Raghupathy R
Lupus; 2009 Jul; 18(8):690-7. PubMed ID: 19502264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
